Identification of novel functional inhibitors of acid sphingomyelinase

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Kornhuber, Johannes ^a   Muehlbacher, Markus ^a,b   Trapp, Stefan ^c   Pechmann, Stefanie ^a   Friedl, Astrid ^a   Reichel, Martin ^a   Mühle, Christiane ^a   Terfloth, Lothar ^d   Groemer, Teja W ^a   Spitzer, Gudrun M ^b   Liedl, Klaus R ^b   Gulbins, Erich ^e   Tripal, Philipp ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d Molecular Networks GmbH   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALVERINE; APRINDINE; BIPERIDEN; CARVEDILOL; CEPHARANTHINE; CLEMASTINE; CLOFAZIMINE; CONESSINE; DESLORATADINE; DICYCLOVERINE; DIMEBON; EMETINE; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; HYDROXYZINE; LOPERAMIDE; MEBEVERINE; MEBHYDROLIN; MIBEFRADIL; NATURAL PRODUCT; PERPHENAZINE; PIMOZIDE; PROFENAMINE; SERTINDOLE; SOLASODINE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; TOMATINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT; ENZYME INHIBITOR;

ALKALINITY; ARTICLE; BLOOD BRAIN BARRIER; CLUSTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPOPHILICITY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; PHYSICAL CHEMISTRY; RESIDUE ANALYSIS; STRUCTURE ACTIVITY RELATION; COMPUTER INTERFACE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; REPRODUCIBILITY; TUMOR CELL LINE;

BIOLOGICAL AGENTS; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; REPRODUCIBILITY OF RESULTS; SPHINGOMYELIN PHOSPHODIESTERASE; USER-COMPUTER INTERFACE;

EID: 80052314330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023852     Document Type: Article

References (137)

1. Jin S, Yi F, Zhang F, Poklis JL, Li PL, (2008) Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells. Arterioscler Thromb Vasc Biol 28: 2056-2062.
2. Hannun YA, Luberto C, (2000) Ceramide in the eukaryotic stress response. Trends Cell Biol 10: 73-80.
3. Castillo SS, Levy M, Thaikoottathil JV, Goldkorn T, (2007) Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp Cell Res 313: 2680-2686.
4. Grassmé H, Jekle A, Riehle A, Schwarz H, Berger J, et al. (2001) CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 276: 20589-20596.
5. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, et al. (2003) Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 9: 322-330.
6. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, et al. (1995) FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2: 341-351.
7. Chung HS, Park SR, Choi EK, Park HJ, Griffin RJ, et al. (2003) Role of sphingomyelin-MAPKs pathway in heat-induced apoptosis. Exp Mol Med 35: 181-188.
8. Rebillard A, Rioux-Leclercq N, Muller C, Bellaud P, Jouan F, et al. (2008) Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage. Oncogene 27: 6590-6595.
9. Santana P, Peña LA, Haimovitz-Friedman A, Martin S, Green D, et al. (1996) Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86: 189-199.
10. Kirschnek S, Paris F, Weller M, Grassmé H, Ferlinz K, et al. (2000) CD95-mediated apoptosis in vivo involves acid sphingomyelinase. J Biol Chem 275: 27316-27323.
11. Jenkins RW, Canals D, Hannun YA, (2009) Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 21: 836-846.
12. Schwarz A, Futerman AH, (1997) Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J Neurosci 17: 2929-2938.
13. Futerman AH, Hannun YA, (2004) The complex life of simple sphingolipids. EMBO Rep 5: 777-782.
14. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, et al. (2001) Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291: 1800-1803.
15. Spiegel S, Milstien S, (2002) Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277: 25851-25854.
16. Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, et al. (2004) Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 166: 381-392.
17. Spiegel S, Merrill AH Jr, (1996) Sphingolipid metabolism and cell growth regulation. FASEB J 10: 1388-1397.
18. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, et al. (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803.
19. Spiegel S, Cuvillier O, Edsall LC, Kohama T, Menzeleev R, et al. (1998) Sphingosine-1-phosphate in cell growth and cell death. Ann N Y Acad Sci 845: 11-18.
20. Brady RO, Kanfer JN, Mock MB, Fredrickson DS, (1966) The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci U S A 55: 366-369.
21. Schuchman EH, Miranda SRP, (1997) Niemann-Pick disease: Mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test 1: 13-19.
22. Smith EL, Schuchman EH, (2008) The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J 22: 3419-3431.
23. Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, et al. (2005) High activity of acid sphingomyelinase in major depression. J Neural Transm 112: 1583-1590.
24. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, et al. (2008) High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7: 4266-4277.
25. Kornhuber J, Reichel M, Tripal P, Groemer TW, Henkel AW, et al. (2009) The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 259: S199-S204.
26. Ndengele MN, Cuzzocrea S, Masini E, Vinci MC, Esposito E, et al. (2009) Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 329: 64-75.
27. Malaplate-Armand C, Florent-Béchard S, Youssef I, Koziel V, Sponne I, et al. (2006) Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 23: 178-189.
28. He X, Huang Y, Li B, Gong C-X, Schuchman EH, (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31: 398-408.
29. Han X, Holtzman M, McKeel DW Jr, Kelley J, Morris JC, (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82: 809-818.
30. Cuzzocrea S, Deigner H-P, Genovese T, Mazzon E, Esposito E, et al. (2009) Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury. Shock 31: 634-644.
31. Mikati MA, Zeinieh M, Habib RA, El HJ, Rahmeh A, et al. (2008) Changes in sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus. Epilepsy Res 81: 161-166.
32. Kolesnick R, (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110: 3-8.
33. Gulbins E, Li PL, (2006) Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 290: R11-R26.
34. Thevissen K, François IEJA, Winderickx J, Pannecouque C, Cammue BPA, (2006) Ceramide involvement in apoptosis and apoptotic diseases. Mini Rev Med Chem 6: 699-709.
35. Deigner HP, Haberkorn U, Kinscherf R, (2000) Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs 9: 747-764.
36. Pandey S, Murphy RF, Agrawal DK, (2007) Recent advances in the immunobiology of ceramide. Exp Mol Pathol 82: 298-309.
37. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, et al. (1993) Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262: 659-700.
38. Kornhuber J, Retz W, Riederer P, (1995) Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J Neural Transm Suppl 46: 311-319.
39. Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, et al. (2010) Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 26: 9-20.
40. Testai FD, Landek MA, Goswami R, Ahmed M, Dawson G, (2004) Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. J Neurochem 89: 636-644.
41. Kölzer M, Arenz C, Ferlinz K, Werth N, Schulze H, et al. (2003) Phosphatidylinositol-3,5-bisphosphate is a potent and selective inhibitor of acid sphingomyelinase. Biol Chem 384: 1293-1298.
42. Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, et al. (2007) Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 122: 54-64.
43. Darroch PI, Dagan A, Granot T, He X, Gatt S, et al. (2005) A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death. J Lipid Res 46: 2315-2324.
44. Mintzer RJ, Appell KC, Cole A, Johns A, Pagila R, et al. (2005) A novel high-throughput screening format to identify inhibitors of secreted acid sphingomyelinase. J Biomol Screen 10: 225-234.
45. Albouz S, Hauw JJ, Berwald-Netter Y, Boutry JM, Bourdon R, et al. (1981) Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedicine 35: 218-220.
46. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, et al. (1985) Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem (Tokyo) 98: 1669-1679.
47. Sakuragawa N, Sakuragawa M, Kuwabara T, Pentchev PG, Barranger JA, et al. (1977) Niemann-Pick disease experimental model: sphingomyelinase reduction induced by AY-9944. Science 196: 317-319.
48. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, et al. (1974) Lysosomotropic agents. Biochem Pharmacol 23: 2495-2531.
49. Trapp S, Rosania GR, Horobin RW, Kornhuber J, (2008) Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J 37: 1317-1328.
50. Kölzer M, Werth N, Sandhoff K, (2004) Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 559: 96-98.
51. Hurwitz R, Ferlinz K, Sandhoff K, (1994) The tricyclic antidepressants desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 375: 447-450.
52. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, et al. (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 51: 219-237.
53. Altman DG, Royston P, (2006) The cost of dichotomising continuous variables. BMJ 332: 1080.
54. Streiner DL, (2002) Breaking up is hard to do: The heartbreak of dichotomizing continuous data. Can J Psychiatry 47: 262-266.
55. Ragland DR, (1992) Dichotomizing continuous outcome variables: Dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology 3: 434-440.
56. Lanevskij K, Japertas P, Didziapetris R, Petrauskas A, (2009) Ionization-specific prediction of blood-brain permeability. J Pharm Sci 98: 122-134.
57. Levin VA, (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23: 682-684.
58. Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A, (2008) QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res 25: 1902-1914.
59. Todeschini R, Consonni V, (2000) Handbook of Molecular Descriptors Weinheim, Germany Wiley-VCH.
60. Tropsha A, Gramatica P, Gombar VK, (2003) The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 22: 69-77.
61. von der Voet H, (1994) Comparing the predictive accuracy of models using a simple randomization test. Chemom Intell Lab Syst 25: 313-323.
62. [Anonymous] (2007) Guidance document on the validation of (quantitative) structure-activity relationship [(Q)SAR] modelds. No. 69: 1-154 OECD: Organisation for economic co-operation and development. IOMC: Inter-organization programme for the sound management of chemicals.
63. Bradbury MW, (1993) The blood-brain barrier. Exp Physiol 78: 453-472.
64. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, et al. (2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6: 650-661.
65. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and developmental settings. Adv Drug Deliv Rev 23: 3-25.
66. Micro Source Discovery Pure Natural Products. Available: http://www.msdiscovery.com/natprod.html. Accessed: 2011 Aug 12.
67. Willett P, (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11: 1046-1053.
68. Akella LB, Decaprio D, (2010) Cheminformatics approaches to analyze diversity in compound screening libraries. Curr Opin Chem Biol 14: 325-330.
69. The WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health The ATC/DDD System. Available: http://www.whocc.no/atcddd/. Accessed: 2011 Aug 12.
70. [Anonymous] (2007) Approved Drug Products with Therapeutic Equivalence Evaluations U.S. Department of Health and Human Servies. Food and Drug Administration. Center for Drug Evaluation and Research. Office of Pharmaceutical Science. Office of Generic Drugs.
71. Yu ZF, Nikolova-Karakashian M, Zhou D, Cheng G, Schuchman EH, et al. (2000) Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci 15: 85-97.
72. Altura BM, Gebrewold A, Zheng T, Altura BT, (2002) Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke. Brain Res Bull 58: 271-278.
73. Pascual M, Valles SL, Renau-Piqueras J, Guerri C, (2003) Ceramide pathways modulate ethanol-induced cell death in astrocytes. J Neurochem 87: 1535-1545.
74. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, et al. (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297.
75. Van Veldhoven PP, Matthews TJ, Bolognesi DP, Bell RM, (1992) Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem Biophys Res Commun 187: 209-216.
76. De Simone C, Cifone GM, Roncaioli P, Moretti S, Famularo G, et al. (1996) Ceramide, AIDS and long-term survivors. Immunol Today 17: 48.
77. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, et al. (1995) Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332: 209-216.
78. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, et al. (1997) Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 186: 1831-1841.
79. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, et al. (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14: 382-391.
80. Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, et al. (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42: 716-724.
81. Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, et al. (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24: 65-72.
82. Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, et al. (2004) PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 10: 155-160.
83. Dawson G, Qin J, (2011) Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. Biochem Biophys Res Commun 404: 321-323 doi:10.1016/j.bbrc.2010.11.115.
84. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, et al. (2006) New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 580: 4751-4756.
85. Canals D, Perry DM, Jenkins RW, Hannun YA, (2011) Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 163: 694-712 doi:10.1111/j.1476-5381.2011.01279.x.
86. Advanced Chemistry Development Inc ACD/LogD Suite. Available: http://www.acdlabs.com. Accessed: 2011 Aug 12.
87. National Center for Biotechnology Information USA PubChem-Project. Available: http://pubchem.ncbi.nlm.nih.gov. Accessed: 2011 Aug 12.
88. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 37: W623-W633.
89. Gulbins E, Kolesnick R, (2000) Measurement of sphingomyelinase activity. Methods Enzymol 322: 382-388.
90. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300.
91. R Development Core Team R Development Core Team. Available: http://www.r-project.org. Accessed: 2011 Aug 12.
92. [Anonymous] MOE Molecular Operating Environment. Available: http://www.chemcomp.com. Accessed: 2011 Aug 12.
93. Gerebtzoff G, Seelig A, (2006) In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J Chem Inf Model 46: 2638-2650.
94. Fischer H, Gottschlich R, Seelig A, (1998) Blood-brain barrier permeation: Molecular parameters governing passive diffusion. J Membr Biol 165: 201-211.
95. Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J, (2011) Critical analysis of cross-sectional area for blood-brain barrier prediction on a large scale dataset. J Comput-Aided Mol Des, under review; manuscript available on request (Johannes.Kornhuber@uk-erlangen.de).
96. Purvis GD 3rd, (2008) Size-intensive descriptors. J Comput Aided Mol Des 22: 461-468.
97. Meloun M, Bordovská S, (2007) Benchmarking and validating algorithms that estimate pKa values of drugs based on their molecular structures. Anal Bioanal Chem 389: 1267-1281.
98. Mierswa I, Wurst M, Klinkenberg R, Scholz M, Euler T, (2006) YALE: Rapid prototyping for complex data mining tasks. In: Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD-06).
99. Amaratunga D, Cabrera J, Lee Y-S, (2008) Enriched random forests. Bioinformatics 24: 2010-2014.
100. Saeys Y, Inza I, Larranaga P, (2007) A review of feature selection techniques in bioinformatics. Bioinformatics 23: 2507-2517.
101. Guyon I, Elisseeff A, (2003) An introduction of variable and feature selection. J Machine Learning Res 3: 1157-1182.
102. Kohavi R, John GH, (1997) Wrappers for feature subset selection. Artificial Intelligence 97: 273-324.
103. Kononenko I, (1994) Estimating attributes: Analysis and extensions of relief. Proceedings of the Seventh European Conference on Machine Learning Springer Verlag pp. 171-182.
104. Kira K, Rendell L, (1992) The feature selection problem: traditional methods and a new algorithm. Proceedings of the Tenth National Conference on Artificial Intelligence Penlo Park AAAI Press/The MIT Press pp. 129-134.
105. Witten IH, Frank E, (2005) Data Mining. Practical Machine Learning Tools and Techniques Amsterdam Elsevier.
106. Alpaydin E, (2008) Maschinelles Lernen München Oldenbourg Wissenschaftsverlag GmbH.
107. Roecker EB, (1991) Prediction error and its estimation for subset-selected models. Technometrics 33: 459-468.
108. Bisiani R, (1987) Beam search. In: Shapiro S, Eckroth D, editors. Encyclopedia of Artificial Intelligence New York Wiley & Sons pp. 56-58.
109. Youden WJ, (1950) Index for rating diagnostic tests. Cancer 3: 32-35.
110. Fluss R, Faraggi D, Reiser B, (2005) Estimation of the Youden Index and its associated cutoff point. Biom J 47: 458-472.
111. Bush WS, Edwards TL, Dudek SM, McKinney BA, Ritchie MD, (2008) Alternative contingency table measures improve the power and detection of multifactor dimensionality reduction. BMC Bioinformatics 9: 238.
112. Breiman L, (2001) Random Forests. Machine Learning 45: 5-32.
113. Zhou ZH, (2009) Ensemble Learning. In: Li SZ, editors. Encyclopedia of Biometrics Berlin Springer pp. 270-273.
114. Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, et al. (2003) Random forest: A classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci 43: 1947-1958.
115. Wold S, Eriksson L, (1995) Statistical validation of QSAR results. In: van de Waterbeemd H, editors. Chemometrics Methods in Molecular Design Weinheim VHC pp. 309-318.
116. Ewing T, Baber JC, Feher M, (2006) Novel 2D fingerprints for ligand-based virtual screening. J Chem Inf Model 46: 2423-2431 doi:10.1021/ci060155b.
117. Williams C, (2006) Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance. Mol Divers 10: 311-332 doi:10.1007/s11030-006-9039-z.
118. Narayanan R, Gunturi SB, (2005) In silico ADME modelling: Prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg Med Chem 13: 3017-3028.
119. Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen JP, (1999) Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 16: 1514-1519.
120. Garg P, Verma J, (2006) In silico prediction of blood brain barrier permeability: An artificial neural network model. J Chem Inf Model 46: 289-297.
121. Rose K, Hall LH, Kier LB, (2002) Modeling blood-brain barrier partitioning using the electrotopological state. J Chem Inf Comput Sci 42: 651-666.
122. Abraham MH, Ibrahim A, Zhao Y, Acree WE Jr, (2006) A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J Pharm Sci 95: 2091-2100.
123. Guerra A, Páez JA, Campillo NE, (2008) Artificial neural networks in ADMET modeling: prediction of blood-brain barrier permeation. QSAR & Combinatorial Sci 27: 586-594.
124. Konovalov DA, Coomans D, Deconinck E, Heyden YV, (2007) Benchmarking of QSAR models for blood-brain barrier permeation. J Chem Inf Model 47: 1648-1656.
125. Zerara M, Brickmann J, Kretschmer R, Exner TE, (2009) Parameterization of an empirical model for the prediction of n-octanol, alkane and cyclohexane/water as well as brain/blood partition coefficients. J Comput Aided Mol Des 23: 105-111.
126. Vilar S, Chakrabarti M, Costanzi S, (2010) Prediction of passive blood-brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model 28: 899-903 doi:10.1016/j.jmgm.2010.03.010.
127. Mente SR, Lombardo F, (2005) A recursive-partitioning model for blood-brain barrier permeation. J Comput Aided Mol Des 19: 465-481 doi:10.1007/s10822-005-9001-7.
128. Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, et al. (2001) Correlation and prediction of a large blood-brain distribution data set- an LFER study. Eur J Med Chem 36: 719-730.
129. [Anonymous] (1981) [The new classification of drugs: the ATC-code now introduced]. Ugeskr Laeger 143: 1037-1039.
130. [Anonymous] (2004) The selection and use of essential medicines. World Health Organ Tech Rep Ser 920: 1-127.
131. Goede A, Dunkel M, Mester N, Frommel C, Preissner R, (2005) SuperDrug: a conformational drug database. Bioinformatics 21: 1751-1753.
132. Cox MK, Key CH, (1993) Post hoc pair-wise comparisons for the chi-square test of homogeneity of proportions. Educational and Psychological Measurement 53: 951-962.
133. Andres C, Hutter MC, (2006) CNS permeability of drugs predicted by a decision tree. QSAR Comb Sci 25: 305-309.
134. Norinder U, Haeberlein M, (2002) Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 54: 291-313.
135. Fu X-C, Wang G-P, Shan H-L, Liang W-Q, Gao J-Q, (2008) Predicting blood-brain barrier penetration from molecular weight and number of polar atoms. Eur J Pharm Biopharm 70: 462-466.
136. Feher M, Sourial E, Schmidt JM, (2000) A simple model for the prediction of blood-brain partitioning. Int J Pharm 201: 239-247.
137. Liu R, Sun H, So SS, (2001) Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J Chem Inf Comput Sci 41: 1623-1632.